A Phase II Study of Paclitaxel, UFT, and Leucovorin in Patients With Metastatic Esophageal Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is for patients with esophageal cancer that has spread to other areas. The purpose of this study is to:

1. Determine how well a combination of taxol, UFT, and leucovorin work in these patients,
2. Determine the survival of patients with metastatic esophageal carcinoma treated with this combination of drugs.
3. Identify the side effects of this drug combination.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Esophageal Neoplasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

UFT (Tegafur/Uracil)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologic proof of esophageal cancer
* No more than one prior non-taxane chemotherapy regimen for either treatment of localized disease or metastatic disease AND they may not have received a regimen containing low dose continuous infusion of 5-FU (i.e. \>5 days of infusion/cycle), capecitabine or UFT
* No prior therapy with UFT+/-leucovorin, a taxane, capecitabine, low dose continuous infusion of 5-FU or ethynyl uracil.
* Radiographic or physical examination documentation of metastatic disease
* No major surgery within the 2 weeks preceding the start of treatment and fully recovered from any complications of surgery
* No radiation within 2 weeks of beginning chemotherapy.
* No chemotherapy within 4 weeks of beginning treatment.
* Patients must wait at least 6 weeks after receiving BCNU or Mitomycin-C.
* Minimum life expectancy of 3 months
* Informed consent given
* Laboratory values within limits set by study.

EXCLUSION

* More than one prior chemotherapy regimen for metastatic disease
* Current serious medical or psychiatric illness that would prevent informed consent or intensive treatment
* \>grade 1 peripheral sensory or motor neuropathy
* Pregnant
* Patient is taking the drug Sorivudine

Minimum Eligible Age

18 Years

Maximum Eligible Age

79 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Maryland Cancer Center

Baltimore, Maryland, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UMCC 0110g

Identifier Type: -

Identifier Source: secondary_id

BMS-200604